Medico Remedies DuPont analysis

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023
5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage
0.73×0.73×0.75×0.73×0.72×
1.31×1.30×1.13×1.13×1.46×
6.1%6.8%7.9%6.9%4.9%
1.51×1.51×1.40×1.58×1.61×
2.03×2.03×1.92×1.84×1.99×
17.9%19.5%18.0%16.6%16.6%
19.0%19.0%17.6%17.2%16.5%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

MEDICO₹19.22

Medico Remedies Limited

· Pharma & Health
₹ CrorePeersMEDICAMEQHALEOSLABSAAREYDRUGSNECLIFEALBERTDAVDVALIANTLABNATCAPSUQZIMLABMcap ₹160 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×0.720.730.750.730.73
Interest Burden (Pretax/EBIT) ×1.461.131.131.301.31
EBIT Margin %4.916.927.936.756.08
Asset Turnover ×1.611.581.401.511.51
Financial Leverage (Assets/Equity) ×1.991.841.922.032.03
ROE (5-step product, year-end total equity) %16.5616.6017.9819.5017.85
ROE (owners' profit / average owners' equity) %16.5217.2317.6019.0419.04
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.